Construct: ORF ccsbBroadEn_03567
Construct Description:
- Construct Type:
- ORF
- Other Identifiers:
- ORF017927.1_s300c1, BRDN0000395189
- DNA Barcode:
- None
- Epitope Tag:
- None
- Notes:
- No stop codon in insert
Originally Annotated References:
- Gene:
- CASC1 (55259)
Vector Information:
- Vector Backbone:
- pDONR223
- Pol II Cassette 1:
- n/a
- Pol II Cassette 2:
- n/a
- Selection Marker:
- n/a
- Visible Reporter:
- n/a
- Epitope Tag:
- n/a
Current transcripts matched by this ORF:
| Taxon | Gene | Symbol | Description | Transcript | Nuc. Match %[?]A simple nucleotide-based global alignment percentage, calculated as follows: total nt. matches ---------------------------------- aligned length (incl. gaps) |
Prot. Match %[?]A simple amino acid-based global alignment percentage, calculated as follows: total aa. matches ---------------------------------- aligned length (incl. gaps) |
Match Diffs[?]This field may contain sequence annotations in HGVS format. For more information about HGVS annotations, please refer to the HGVS Quick Reference Guide. | |
|---|---|---|---|---|---|---|---|---|
| 1 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001082973.3 | 99.9% | 99.8% | 1898C>A |
| 2 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_018272.5 | 99% | 98.8% | 1_18del;20A>T;1916C>A |
| 3 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001204102.3 | 94.3% | 94.2% | 0_1ins120;1778C>A |
| 4 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001319978.2 | 94.3% | 94.2% | 0_1ins120;1778C>A |
| 5 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352061.2 | 94.3% | 94.2% | 0_1ins120;1778C>A |
| 6 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_017019560.1 | 92.3% | 92.2% | 1_175del;176_177insT;2072C>A |
| 7 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_005253406.1 | 91.7% | 91.5% | 1_192del;194A>T;2090C>A |
| 8 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_011520723.1 | 91.7% | 91.5% | 1_192del;194A>T;2090C>A |
| 9 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001204101.3 | 91.6% | 91.4% | 0_1ins177;2_3delTGinsAA;1721C>A |
| 10 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352062.2 | 87.3% | 87.2% | 1876_1877delTGinsGT;1878_1879ins270 |
| 11 | human | 55259 | CASC1 | cancer susceptibility 1 | NR_147909.2 | 85.5% | (many diffs) | |
| 12 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352064.2 | 85.1% | 85% | 1058_1059ins318;1580C>A |
| 13 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352063.2 | 84.3% | 84.2% | (many diffs) |
| 14 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352065.2 | 84.3% | 84.2% | 0_1ins336;1562C>A |
| 15 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_005253408.1 | 84.3% | 84.2% | 0_1ins336;1562C>A |
| 16 | human | 55259 | CASC1 | cancer susceptibility 1 | NR_147911.2 | 82.1% | (many diffs) | |
| 17 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_024449031.1 | 81.7% | 81.7% | 0_1ins120;1756_1757delTGinsGT;1758_1759ins270 |
| 18 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001082972.3 | 80.1% | 80% | (many diffs) |
| 19 | human | 55259 | CASC1 | cancer susceptibility 1 | XR_001748797.1 | 79.7% | (many diffs) | |
| 20 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352066.2 | 79.5% | 79.4% | 0_1ins120;938_939ins318;1460C>A |
| 21 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_006719101.1 | 78.1% | 77.9% | (many diffs) |
| 22 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352067.2 | 76.8% | 76.6% | (many diffs) |
| 23 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001319977.2 | 71.6% | 71.6% | 0_1ins336;1540_1541delTGinsGT;1542_1543ins270 |
| 24 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352068.2 | 66.9% | 66.8% | (many diffs) |
| 25 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_017019565.1 | 66.5% | 66.4% | (many diffs) |
| 26 | human | 55259 | CASC1 | cancer susceptibility 1 | NR_147910.2 | 60.8% | (many diffs) | |
| 27 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_011520726.1 | 60.4% | 58% | (many diffs) |
| 28 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_011520727.1 | 58.2% | 58.2% | 1_192del;194A>T;1557_1558ins783 |
Sequence Information
Note: uppercase bases indicate empirically verified sequence.
- ORF start:
- 69
- ORF end:
- 2217
- ORF length:
- 2148
- Sequence:
-
1 gttcgttgca acaaattgat gagcaatgct tttttataat gccaacttTG TACAAAAAAG 61 TTGGCACCAT GTCTGGCAGT AAGAAAAAGA AAGTCACCAA AGCTGAACGA TTGAAGCTGC 121 TACAAGAGGA GGAGGAGAGA CGACTGAAAG AGGAAGAGGA AGCCCGTTTG AAATATGAGA 181 AAGAAGAAAT GGAAAGGCTT GAAATACAGC GAATTGAGAA AGAAAAATGG CATCGACTTG 241 AAGCAAAAGA TCTAGAAAGG AGAAATGAAG AACTTGAAGA ACTTTATTTA TTAGAGAGGT 301 GTTTTCCTGA AGCAGAGAAA TTGAAACAGG AAACTAAATT GCTTTCTCAG TGGAAGCACT 361 ACATTCAATG TGATGGGAGT CCTGATCCTT CAGTAGCCCA AGAAATGAAC ACGTTTATTA 421 GTTTGTGGAA AGAGAAAACA AATGAGACTT TTGAGGAAGT GATTGAGAAG AGTAAAGTAG 481 TGCTAAATTT AATTGAGAAA TTGAAATTTA TTTTACTGGA AACTCCACCA TGTGATTTGC 541 AAGATAAAAA TATAATACAG TACCAAGAAT CAATACTACA ACTGCAGGAG CTCCTTCATC 601 TTAAATTCGG TGTAGCCACA GAAATACTTC TCAAACAAGC TAGTACTTTG GCAGATCTGG 661 ACAGTGGAAA TATGGAAAAA GTCATTAAAG ATGAAAATGT TACTCTGTAT GTGTGGGCAA 721 ACCTCAAGAA GAATCCAAGG CACAGAAGTG TTAGATTCTC TGAAACACAA ATTGGATTTG 781 AGATTCCAAG GATATTAGCA ACAAGTGACA TTGCTGTACG ACTCCTGCAT ACCCACTATG 841 ATCATGTTTC TGCACTGCAC CCTGTTTCAA CACCATCAAA AGAATACACT TCTGCAGTAA 901 CTGAGCTTGT CAAAGATGAT GTTAAGAATG TAGAAAAAGC AATCAGCAAG GAGGTCGAAG 961 AAGAGTCCAA ACAACAAGAA AGAGGGTCTC ACTTAATTCA GGAGGAAGAA ATAAAAGTTG 1021 AGGAGGAACA AGGTGATATT GAAGTGAAAA TGAGTTCTGC TGAGGAAGAA TCTGAAGCCA 1081 TAAAATGTGA ACGAGAGATG AAAGTATTAA GTGAAACTGT TTCAGCAGCA CAGTTGTTGC 1141 TGGTAGAGAA TTCTTCTGAA AAGCCAGATT TCTTTGAAGA CAATGTGGTG GATTTATGCC 1201 AGTTCACAAC TCTGGGTGGA GTATACCACT TGGATATTTT GGAGCTTCCT CCACAGTGTA 1261 AACCAGTGAA GGGATGGATG ATTGTGGAAA TACTCAAAGA AGGATTACAG AAATACACAT 1321 ATCCTCCGGA AACTACAGAA GAGTTTGAGA CAGAAAATGC TTTCCCACCT ATAGAGGTCA 1381 CACTTGAGGT TCATGAGAAT GTAATCTTTT TTGAGGATCC TGTGGTTGTA AGGTGGGATG 1441 CTGAAGGTAA ACATTGGAGA ACTGATGGCA TCAGCAATGT ATCCTACAAA CCAAAAGAAA 1501 GACTTGTAAC ATTCAGCCTG GACACCTTTG GCCCTGTTAC CTTGATTCAA GATGCTCATA 1561 TTAACATGCC GTACCAGTCA TGGGAACTAA GACCACTTGA TGTAAATAAA GTACTTTTAA 1621 CTGTGACTAC AGTATTTACT GAGATTCAAA TACAAATTAA GGAAAACCTC TGCATGTTAT 1681 CTTCAATCAA ACTAAAAGAC AAGAAACACA TCTCTATTTT GGAAGGAACC TGGATGACTC 1741 CTATTCCTTT CATTATTGCT TTGAAAGAAG CTGGACTGAA TATCTTTCCT ACTAGACACT 1801 CTCATTTTTA TGTTATTATA AACAATAAGG TTCCTTTGGT AGAAGTGAAA GCTTATCGAC 1861 AGATGGCCCT ACTAAGTTCT GCTTTTGCAT TTGGTTGGAG CAAGTGGAAC CTACTATGTA 1921 ATTCTACAAA AGTCGTATTT AAGGTGAGGG AACACCTTAC TGAAGAATGT ACTGAGAATC 1981 CTAATTGGGC CCTTTTAATG TTTAGTGGTG ACAGAGCACA AAGACTGAAG ATCAAGGAAG 2041 AGAGTGAGGC ATTTTCTGAA GCACTTAAAG AAGAAACTGA GTTTCATTCT ACTTTATATC 2101 ACATGGTGAA GGATTTTGCT TCTGAGGAAG CAATGGAGAA AGTCAGGAGT TCCAACTGTC 2161 AGTTTGTCAA CTCTGTGTGC CACATGCTGC TCTCTACCAG ATTGCTCAGC TACTCCTTGC 2221 CAACTTTCTT GTACAAAGTt ggcattataa gaaagcattg cttatcaatt tgttgcaacg 2281 aac